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The rapid pandemic expansion of the disease caused by the new SARS-CoV-2 virus has
compromised health systems worldwide. Knowledge of prognostic factors in affected
patients can help optimize care.
Objective
The objective of this study was to analyze the relationship between the prognosis of COVID-
19 and the form of presentation of the disease, the previous pathologies of patients and their
chronic treatments.
Design, participants and locations
This was an observational study on a cohort of 418 patients admitted to three regional hospi-
tals in Catalonia (Spain). As primary outcomes, severe disease (need for oxygen therapy
via nonrebreather mask or mechanical ventilation) and death were studied. Multivariate
binary logistic regression models were performed to study the association between the dif-
ferent factors and the results.
Results
Advanced age, male sex and obesity were independent markers of poor prognosis. The
most frequent presenting symptom was fever, while dyspnea was associated with severe
disease and the presence of cough with greater survival. Low oxygen saturation in the emer-
gency room, elevated CRP in the emergency room and initial radiological involvement were
all related to worse prognosis. The presence of eosinophilia (% of eosinophils) was an inde-
pendent marker of less severe disease.
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Conclusions
This study identified the most robust markers of poor prognosis for COVID-19. These results
can help to correctly stratify patients at the beginning of hospitalization based on the risk of
developing severe disease.
Introduction
Since the appearance of an outbreak of respiratory disease associated with a new coronavirus
(SARS-CoV 2) in Wuhan (China) in December 2019, the spread of this new pathogen in the
world population has been continuous, with a pandemic declared on March 11, 2020. Global
case fatality rate (about 3,6% of total reported cases in the world) and the total number of
affected patients in the world (more than 21 million people on August 16th) makes this new
disease (Covid-19) a target of research priority [1].
All health systems in the world are under enormous healthcare pressure due to this pan-
demic, and Spain has been one of the most affected countries in Europe [1]. In this context,
the identification of risk factors or predictors associated with poor prognosis is relevant in
terms of early detection of the most vulnerable patients and the best organization of available
health resources.
Several studies, including meta-analyses and systematic reviews of cohorts or case series [2–5],
have identified various predictors or risk factors for death and severity in patients hospitalized for
COVID-19. Thus, several baseline factors (older age and male sex), comorbidities (mainly cardio-
vascular pathology), symptoms (dyspnea) and clinical parameters (respiratory function, inflam-
matory markers and lymphopenia) associated with worse prognosis have been identified.
However, the vast majority of these studies come from Asian cohorts, mainly from China. This
difference is important because in addition to ethnicity, other determining factors, such as age or
associated comorbidity, are quite different. In two reviews of comorbidities in patients with
COVID-19 of Asian origin (16 studies, N = 78 520) [6, 7], a relatively low prevalence of hyperten-
sion and diabetes mellitus (16–17% and 12–16%, respectively) was reported compared to popula-
tions in our environment, such as those analyzed in two Italian cohort studies [8, 9], in which a
prevalence of arterial hypertension of 50% and of diabetes mellitus of 17–22% were reported. In
Europe, risk factors or predictors have been reported mainly from cohorts of Italy [8–10], the
other European country most affected by the pandemic. In Spain, as far as we know, studies of
reported risk factors have considered only specific subpopulations, such as renal replacement
therapy patients or oncology patients [11–13], or specific laboratory parameters [14].
In the reported cohorts, the association of various chronic pharmacological treatments
(with the exception of renin angiotensin-aldosterone blockers) [15–17] with poor prognosis
events in COVID-19 patients has not been evaluated. We believe that an exhaustive explora-
tion of this issue is relevant given the high consumption of pharmacological treatments for var-
ious chronic pathologies in the countries around us.
Therefore, in this study, we studied the association of various baseline, pharmacological,
clinical, radiological and laboratory parameters with adverse clinical events (severe disease and
death) in a cohort of patients hospitalized in our health centers.
Materials and methods
This was an observational cohort study on a sample of 418 patients admitted for COVID-19 to
the hospitals of the Consorci Sanitari de l’Alt Penedès i Garraf (CSAPG). The CSAPG is a
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consortium of three regional hospitals, serving a total population of 247,357 inhabitants. Dur-
ing the study period, in the reference population served by our hospitals, a total of 1,442 diag-
noses of COVID-19 were made by PCR test for SARS-CoV-2 (including community and
hospitalized patients). However, this figures does not reflect the incidence of the disease in our
area, since PCR test was not performed to patients with mild symptoms, who did not require
medical care.
All patients admitted to hour hospitals with a clinical syndrome consistent with COVID-19
were included in the study; those with a negative PCR test for SARS-CoV-2 via nasal smear
and those without respiratory involvement were excluded. The data were collected ambispec-
tively, with data collection beginning on April 6, 2020. The data collected corresponded to
patients admitted consecutively between the 12ve of March 2020 and the 2nd of May 2020.
Information was collected from each patient from the first day of admission until death or
discharge.
The data were collected from electronic medical records by the COVID-19 research group
of CSAPG, with the help of a digital Case Report Form created in OpenClinica, version 3.1.
(Copyright © OpenClinica LLC and collaborators, Waltham, MA, USA). The researchers who
collected the data were health care personnel from the center, who received specific training in
the data collection procedures. During the data collection process, quality controls were estab-
lished for the data collected, e.g. checking their consistency and verifying, with the source doc-
ument, at least 20% of the main variable data. Detected errors were corrected, and when
necessary, the responsible researcher was retrained.
Death and severe disease were taken as outcome variables. The latter was defined as the
need for oxygen therapy through a nonrebreather mask (approximate inspired fraction of oxy-
gen: 100%) or mechanical ventilation (invasive, noninvasive or high flow nasal cannula).
As exposure variables or risk markers, sex, age and the following blocks of variables were
analyzed: (1) previous diseases (comorbidities) and chronic treatments prescribed before
admission, (2) data related to the disease presentation of COVID-19 and (3) laboratory analyti-
cal parameters at the time of admission.
Previous disease history of the patient was collected dichotomously (Yes/No) after detailed
reading of all available patient reports. The list of pathologies recorded in the database
included cardiovascular, respiratory, digestive, renal, neoplastic, autoimmune, psychiatric,
neurological and other diseases. The complete list of pathologies registered in the database is
shown in Table 1.
Chronic treatments prescribed to the patients were also recorded dichotomously (Yes/No)
after detailed consultation of the available patient reports and electronic prescriptions. The list
of registered drugs included antiplatelet and anticoagulant drugs, analgesics, anti-inflammato-
ries, antidiabetic drugs, drugs for cardiovascular diseases, drugs for the respiratory system,
drugs with an effect on the central nervous system, cytotoxic drugs and drugs with action on
the immune system, among others. A complete list of registered therapies is also shown in
Table 1.
Regarding the disease presentation of COVID-19, the symptoms reported in the emergency
reports (dichotomously: cough, fever, dyspnea, anosmia, dysgeusia, diarrhea, arthromyalgia,
severe asthenia, skin lesions, headache and confusion), baseline oxygen saturation in the emer-
gency room, affected quadrants on the first chest radiography (range: 0 to 4 quadrants) and C-
reactive protein (CRP; mg/L) in the emergency room were recorded.
The following analytical parameters were recorded at admission: PCR results for SARS-
CoV-2, hemoglobin, platelets, neutrophils (absolute and percentage), lymphocytes (absolute
and percentage), eosinophils, prothrombin time (INR), D-dimer, fibrinogen, glycemia,
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Table 1. Chronic conditions and treatments of hospitalized patients with COVID-19.
Total Mild D. Severe D. OR (95% CI) p� Survived Deceased OR (95% CI) p�
N n (%) n (%) n (%) n (%)
Male sex 238 94 (39.5) 144 (60.5) 1.73 (1.17–2.57) 0.010 193 (81.1) 45 (18.9) 0.99 (0.61–1.64) 1.000
Age (mean) 418 189 (63.6) 229 (66.9) - 0.180 339 (61.9) 79 (80.4) - <0.001
Chronic kidney disease 61 20 (32.8) 41 (67.2) 1.83 (1.04–3.32) 0.160 34 (55.7) 27 (44.3) 4.64 (2.57–8.34) <0.001
Hypertension 217 88 (40.6) 129 (59.4) 1.48 (1.00–2.18) 0.189 152 (70.0) 65 (30.0) 5.64 (3.13–1087) <0.001
Diabetes 99 35 (35.4) 64 (64.6) 1.70 (1.07–2.74) 0.134 66 (66.7) 33 (33.3) 2.96 (1.75–4.99) <0.001
Dyslipidemia 145 55 (37.9) 90 (62.1) 1.57 (1.05–2.39) 0.141 107 (73.8) 38 (26.2) 2.01 (1.22–3.31) 0.026
Obesity 74 23 (31.1) 51 (68.9) 2.06 (1.22–3.58) 0.050 59 (79.7) 15 (20.3) 1.12 (0.58–2.06) 0.879
Smoking 36 16 (44.4) 20 (55.6) 1.03 (0.52–2.10) 1.000 33 (91.7) 3 (8.3) 0.38 (0.09–1.11) 0.228
Alcoholism 11 1 (9.1) 10 (90.9) 7.59 (1.42–188.85) 0.089 10 (90.9) 1 (9.1) 0.48 (0.02–2.57) 0.840
Heart failure 26 9 (34.6) 17 (65.4) 1.59 (0.70–3.85) 0.604 13 (50.0) 14 (53.8) 5.82 (2.55–13.49) <0.001
Ischemic heart disease 37 18 (48.6) 19 (51.4) 0.86 (0.43–1.71) 1.000 80 (216.2) 7 (18.9) 1.02 (0.39–2.30) 1.000
Aortic valve disease 10 5 (50.0) 5 (50.0) 0.82 (0.22–3.10) 1.000 2 (20.0) 8 (80.0) 17.81 (4.24–131.51) <0.001
Mitral valve disease 11 9 (27.3) 8 (72.7) 2.17 (0.60–10.57) 0.652 6 (54.5) 5 (45.5) 3.75 (1.02–13.13) 0.091
Pulm. valve disease 2 1 (50.0) 1 (50.0) 0.82 (0.02–32.32) 1.000 2 (100.0) 0 (0.0) - 1.000
Pacemaker 6 3 (50.0) 3 (50.0) 0.82 (0.14–4.84) 1.000 1 (16.7) 5 (83.3) 20.38 (3.07–544.24) 0.004
Other heart disease 9 2 (22.2) 7 (77.8) 2.79 (0.65–20.89) 0.460 4 (44.4) 5 (55.6) 5.58 (1.39–24.06) 0.040
Atrial fibrillation 45 16 (35.6) 29 (64.4) 1.56 (0.83–3.04) 0.477 23 (51.1) 22 (48.9) 5.27 (2.74–10.16) <0.001
Stroke 23 6 (26.1) 17 (73.9) 2.40 (0.97–6.88) 0.248 13 (56.5) 10 (43.5) 3.63 (1.48–8.67) 0.016
Gastropathy 32 13 (40.6) 19 (59.4) 1.22 (0.59–2.61) 1.000 23 (71.9) 9 (28.1) 1.78 (0.75–3.92) 0.283
Inflam. bowel disease 5 3 (60.0) 2 (40.0) 0.56 (0.06–3.71) 0.955 4 (80.0) 1 (20.0) 1.18 (0.04–8.68) 1.000
Celiac disease 3 1 (33.3) 2 (66.7) 1.56 (0.13–49.10) 1.000 3 (100.0) 0 (0.0) - 1.000
Chronic hepatitis C 0 0 0 - 0 0 - -
Other liver disease 24 7 (29.2) 17 (70.8) 2.06 (0.86–5.49) 0.364 17 (70.8) 7 (29.2) 1.86 (0.69–4.53) 0.314
Arthritis 1 0 (0.0) 1 (100.0) - 1.000 1 (100.0) 0 (0.0) - 1.000
Spondyloarthritis 2 1 (50.0) 1 (50.0) 0.82 (0.02–32.32) 1.000 2 (100.0) 0 (0.0) - 1.000
Other autoimmune 18 4 (22.2) 14 (77.8) 2.92 (1.02–10.77) 0.189 10 (55.6) 8 (44.4) 3.70 (1.35–9.85) 0.030
Asthma 23 11 (47.8) 12 (52.2) 0.89 (0.38–2.13) 1.000 21 (91.3) 2 (8.7) 0.42 (0.06–1.49) 0.434
COPD 41 14 (34.1) 27 (65.9) 1.66 (0.85–3.37) 0.364 29 (70.7) 12 (29.3) 1.92 (0.90–3.90) 0.183
OSAS 34 11 (32.4) 23 (67.6) 1.79 (0.86–3.94) 0.372 22 (64.7) 12 (35.3) 2.59 (1.18–5.43) 0.051
Pulmonary hypert. 3 1 (33.3) 2 (66.7) 1.56 (0.13–49.10) 1.000 2 (66.7) 1 (33.3) 2.29 (0.07–28.64) 0.644
Other lung disease 18 7 (38.9) 11 (61.1) 1.30 (0.50–3.66) 0.939 16 (88.9) 2 (11.1) 0.56 (0.08–2.04) 0.727
Depression 63 29 (46.0) 34 (54.0) 0.96 (0.56–1.66) 1.000 45 (71.4) 18 (28.6) 1.93 (1.02–3.53) 0.115
Schizophrenia 4 2 (50.0) 2 (50.0) 0.82 (0.09–7.98) 1.000 2 (50.0) 2 (50.0) 4.36 (0.45–42.37) 0.283
Other psych. dis. 29 13 (44.8) 16 (55.2) 1.01 (0.47–2.22) 1.000 22 (75.9) 7 (24.1) 0.42 (0.54–3.32) 0.644
Dementia 43 19 (44.2) 24 (55.8) 1.05 (0.55–2.00) 1.000 19 (44.2) 24 (55.8) 7.28 (3.74–14.40) <0.001
Parkinson’s disease 2 1 (50.0) 1 (50.0) 0.82 (0.02–32.32) 1.000 1 (50.0) 1 (50.0) 4.31 (0.11–169.14) 0.512
Multiple sclerosis 2 1 (50.0) 1 (50.0) 0.82 (0.02–32.32) 1.000 1 (50.0) 1 (50.0) 4.31 (0.11–169.14) 0.512
Other neurodeg. dis. 9 3 (33.3) 6 (66.7) 1.63 (0.41–8.25) 0.833 5 (55.6) 4 (44.4) 3.57 (0.83–14.33) 0.143
Lung Ca 4 0 (0.0) 4 (100.0) - 0.351 2 (50.0) 2 (50.0) 4.36 (0.45–42.37) 0.283
Breast Ca 7 5 (71.4) 2 (28.6) 0.34 (0.04–1.67) 0.531 6 (85.7) 1 (14.3) 0.79 (0.03–4.91) 1.000
Hepatocell. carcinoma 3 1 (33.3) 2 (66.7) 1.56 (0.13–49.10) 1.000 2 (66.7) 1 (33.3) 2.29 (0.07–28.64) 0.644
Other digestive Ca 7 3 (42.9) 4 (57.1) 1.09 (0.23–5.97) 1.000 5 (71.4) 2 (28.6) 1.81 (0.23–8.96) 0.786
Other cancer 25 11 (44.0) 14 (56.0) 1.05 (0.476–2.44) 1.000 19 (76.0) 6 (24.0) 1.41 (0.49–3.49) 0.771
Hematologic neoplasia 2 1 (50.0) 1 (50.0) 0.82 (0.02–32.32) 1.000 1 (50.0) 1 (50.0) 4.31 (0.11–169.14) 0.512
HIV 3 0 (0.0) 3 (100.0) - 0.531 2 (66.7) 1 (33.3) 2.29 (0.07–28.64) 0.644
Organ transplant 1 0 (0.0) 1 (100.0) - 1.000 1 (100.0) 0 (0.0) - 1.000
(Continued)
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sodium, creatinine, urea, glomerular filtration, transaminases, bilirubin, LDH, CRP, ferritin,
lactate and gasometry parameters.
No a priori calculation of the sample size was made because the intention of the researchers
was to include the total number of patients available during the study period.
In the statistical analysis, the association of each factor collected with the outcomes of inter-
est (serious illness or death) was explored. First, bivariate comparisons were conducted for
each factor with the outcomes, and statistical significance was adjusted according to the high
number of comparisons by using the False Discovery Rate technic [18]. Second, multivariate
Table 1. (Continued)
Total Mild D. Severe D. OR (95% CI) p� Survived Deceased OR (95% CI) p�
N n (%) n (%) n (%) n (%)
Other immunosupr. 5 3 (60.0) 2 (40.0) 0.56 (0.06–3.71) 0.954 5 (100.0) 0 (0.0) - 0.768
Thyroid disease 31 15 (48.4) 16 (51.6) 0.87 (0.41–1.84) 1.000 27 (87.1) 4 (12.9) 0.64 (0.18–1.70) 0.653
Anemia 33 12 (36.4) 21 (63.6) 1.50 (0.71–3.20) 0.652 21 (63.6) 12 (36.4) 2.71 (1.23–5.75) 0.047
Blood dis. not cancer 6 4 (66.7) 2 (33.3) 0.42 (0.05–2.33) 0.717 5 (83.3) 1 (16.7) 0.95 (0.04–6.29) 1.000
Psoriasis 3 2 (66.7) 1 (33.3) 0.44 (0.01–5.44) 0.906 2 (66.7) 1 (33.3) 2.29 (0.07–28.64) 0.644
Paracetamol 100 53 (53.0) 47 (47.0) 0.66 (0.42–1.04) 0.248 74 (74.0) 26 (26.0) 1.76 (1.02–2.99) 0.094
NSAIDs 33 17 (51.5) 16 (48.5) 0.76 (0.37–1.56) 0.768 26 (78.8) 7 (21.2) 1.19 (0.45–2.72) 0.815
Opioids 29 11 (37.9) 18 (62.1) 1.37 (0.64–3.10) 0.747 21 (72.4) 8 (27.6) 1.72 (0.69–3.94) 0.366
Corticosteroids 19 4 (21.1) 15 (78.9) 3.15 (1.11–11.51) 0.151 12 (63.2) 7 (36.8) 2.66 (0.95–6.95) 0.136
Antihistamines 18 9 (50.0) 9 (50.0) 0.81 (0.31–2.17) 1.000 14 (77.8) 4 (22.2) 1.27 (0.34–3.70) 0.886
Antacids 130 51 (39.2) 79 (60.8) 1.42 (0.94–2.18) 0.307 92 (70.8) 38 (29.2) 2.48 (1.50–4.11) 0.002
Insulin 31 13 (41.9) 18 (58.1) 1.15 (0.55–2.48) 1.000 22 (71.0) 9 (29.0) 1.87 (0.78–4.13) 0.277
Metformin 58 19 (32.8) 39 (67.2) 1.83 (1.03–3.35) 0.186 40 (69.0) 18 (31.0) 2.21 (1.16–4.08) 0.047
Antidiabetics 38 14 (36.8) 24 (63.2) 1.46 (0.74–2.98) 0.604 27 (71.1) 11 (28.9) 1.88 (0.85–3.90) 0.239
Lipid-lowering drugs 100 39 (39.0) 61 (61.0) 1.39 (0.88–2.22) 0.408 77 (77.0) 23 (23.0) 1.40 (0.80–2.40) 0.386
Inhaled ipratropium 37 11 (29.7) 26 (70.3) 2.05 (1.01–4.47) 0.195 28 (75.7) 9 (24.3) 1.44 (0.61–3.10) 0.556
Inhaled beta-2 53 16 (30.2) 37 (69.8) 2.07 (1.13–3.96) 0.134 43 (81.1) 10 (18.9) 1.01 (0.46–2.04) 1.000
Inhaled corticosteroid 47 15 (31.9) 32 (68.1) 1.87 (0.99–3.68) 0.202 37 (78.7) 10 (21.3) 1.19 (0.54–2.44) 0.840
Other inhalers 6 3 (50.0) 3 (50.0) 0.82 (0.14–484) 1.000 4 (66.7) 2 (33.3) 2.25 (0.27–12.45) 0.492
Antiplatelet agents 78 30 (38.5) 48 (61.5) 1.40 (0.85–2.34) 0.477 52 (66.7) 26 (33.3) 2.70 (1.54–4.70) 0.003
Anticoagulants 34 15 (44.1) 19 (55.9) 1.05 (0.52–2.16) 1.000 19 (55.9) 15 (44.1) 3.94 (1.87–8.19) 0.002
Diuretics 103 43 (41.7) 60 (58.3) 1.20 (0.77–1.90) 0.726 71 (68.9) 32 (31.1) 2.57 (1.52–4.31) 0.002
Antihypertensives 74 29 (39.2) 45 (60.8) 1.35 (0.81–2.27) 0.604 54 (73.0) 20 (27.0) 1.79 (0.98–3.19) 0.143
Beta-blockers 60 22 (36.7) 38 (63.3) 1.41 (0.80–2.53) 0.531 47 (78.3) 11 (18.3) 1.01 (0.48–2.00) 1.000
ACE inhibitors 93 35 (37.6) 58 (62.4) 1.49 (0.93–2.41) 0.281 71 (76.3) 22 (23.7) 1.46 (0.82–2.53) 0.369
ARA-2 56 20 (35.7) 36 (64.3) 1.57 (0.88–2.87) 0.372 41 (73.2) 15 (26.8) 1.71 (0.87–3.23) 0.260
Antiarrhythmics 15 2 (13.3) 13 (86.7) 5.27 (1.41–37.09) 0.089 7 (46.7) 8 (53.3) 5.30 (1.81–15.87) 0.009
Sedatives 87 31 (35.6) 56 (64.4) 1.64 (1.01–2.73) 0.189 62 (71.3) 25 (28.7) 2.07 (1.18–3.56) 0.038
Antidepressants 90 37 (41.1) 53 (58.9) 1.24 (0.77–1.99) 0.706 61 (67.8) 29 (32.2) 2.64 (1.53–4.50) 0.003
Antipsychotics 42 13 (31.0) 29 (69.0) 1.95 (0.10–4.00) 0.189 16 (38.1) 26 (61.9) 9.78 (4.95–19.90) <0.001
Antiepileptics 14 6 (42.9) 8 (57.1) 1.10 (0.37–3.46) 1.000 9 (64.3) 5 (35.7) 2.50 (0.73–7.60) 0.277
Anti-parkinsonians 4 2 (50.0) 2 (50.0) 0.82 (0.09–7.98) 1.000 1 (25.0) 3 (75.0) 12.16 (1.39–351.81) 0.057
Other- SNC 33 13 (39.4) 20 (60.6) 1.29 (0.63–2.74) 0.906 22 (66.7) 11 (33.3) 2.34 (1.04–4.99) 0.088
Chemotherapy 4 1 (25.0) 3 (75.0) 2.29 (0.26–66.03) 0.939 3 (75.0) 1 (25.0) 1.56 (0.05–13.63) 0.750
Immunotherapy 13 5 (38.5) 8 (61.5) 1.32 (0.42–4.54) 1.000 10 (76.9) 3 (23.1) 1.34 (0.28–4.60) 0.857
�p value is corrected for multiple comparisons. CNS: Central nervous system. OSAS: Obstructive sleep apnea syndrome.
https://doi.org/10.1371/journal.pone.0239571.t001
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binary logistic regression models were performed with the most relevant factors of each block
of variables, to establish which of the factors were the most robust independent predictors of
death or serious disease. In the multivariate models, both variables with statistical association
with the outcome, as identified in the bivariate models, and variables of clinical relevance in
the opinion of the group of researchers were introduced. Features with less than 15 cases in the
sample, were not included in the multivariable models. The variables finally included in the
model were preselected using the Lasso method [19], this method helps to control multicolli-
nearity problems, which may arise in models with a large number of variables [20]. The labora-
tory parameters underwent a logarithmic transformation, in order to improve their
adjustment to normality, and also they were scaled, to obtain dimensionless variables of zero
mean and standard deviation 1, which would allow Odds Ratio (OR) comparisons between
them. Based on the results, some analyses were repeated in the subgroup of patients younger
than 80 years to mitigate the important effect of age on prognosis, in part due to limited access
to intensive care units, which during the epidemic wave were treating the oldest patients in
Spain.
Missing data were only imputed in the case of laboratory values at admission. When results
of analyses on day one of admission were not available, results of analyses for the second day
were used if available. In this study of prognostic markers, results from analyses performed
beyond the first 48 hours of admission were not included. No other missing data were
imputed.
The authors confirm that all methods were carried out in accordance with relevant guide-
lines and regulations, including the Declaration of Helsinki in its latest version and Regulation
(EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on Data Pro-
tection (RGPD) and other concordant rules. The research ethics committee of the Hospital de
Bellvitge reviewed the study and accepted the waiver of each patient’s informed consent, as
this study was an observational and ambispective review of clinical data, and each patient’s
personal data were anonymized for publication.
Results
Of the 464 patients admitted with clinical suspicion of COVID-19 in the study period, 46
patients were not included in the analysis for having a negative PCR for SARS-CoV-2 (nasal
smear) or not having respiratory involvement. Thus, 418 patients were included in the analy-
sis. The mean age of the sample was 65.4 years (SD 16.6 years), and 43.1% were women. The
median follow-up was 9.5 days (IQR 7 days). All patients were followed until discharge or
until day 30 of admission; therefore, there were no cases censored on the final date of the
study. In total, 79 patients died (18.9%, 95% CI 15.1–22.7%), 25 patients were intubated (6.0%,
95% CI 3.7–8.3%) and 229 patients required oxygen therapy via a nonrebreather mask or
mechanical ventilation (54.8% 95% CI: 50.0–59.6%).
Comorbidities and chronic treatment
The different comorbidities that patients presented as well as the chronic treatment they
received before contracting COVID-19 are shown in Table 1. The same table shows the odds
ratio for death or for developing severe disease associated with each of these factors, as well as
the statistical significance corrected by multiple comparisons (bivariate analysis).
In the multivariate models, male sex and obesity were the risk markers most strongly asso-
ciated with severe disease (need for a nonrebreather mask or mechanical ventilation). In the
total sample, age was the only factor independently associated with death, according to the
multivariate analysis, adjusted for the other relevant factors (Table 2). When the analysis was
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repeated in the subsample of patients younger than 80 years, the only factor that independently
explained case fatality remained age (OR 1.07 for each year added; 95% CI: 1.01–1.12). In mul-
tivariate analyses of the set of chronic treatments prescribed to the participants, which were
also adjusted by age, sex and obesity, corticosteroids (prescribed before contracting the dis-
ease) were an independent predictor of severe disease, and antipsychotics ended up, in the
final as predictors of case fatality (Table 2). To further investigate the effect of corticoids, they
were introduced into a multivariate model of case fatality, adjusted for chronic pathologies
(other than obesity, chronic kidney disease, diabetes and dyslipidemia, were preselected by
Lasso method). In this model, corticosteroids continued to present as an independent risk fac-
tor (OR 3.47 95% CI: 1.09–11.03). Likewise, to rule out that confounding factors prevented
recognizing the risk that we a priori assumed associated with ACE inhibitors, these drugs were
introduced into a multivariate model of case fatality, adjusted for chronic diseases, which did
not show that ACE inhibitors were a risk factor, independent of death or serious illness.
When these analyses were repeated in the subsample of patients younger than 80 years, no
treatment was found to be an independent predictor of severe disease or case fatality.
Disease presentation
The presenting symptoms most frequently reported in histories provided in the emergency
room were, in this order, fever (83.0%), cough (68.9%), dyspnea (59.6%), diarrhea (27.8%),
asthenia (20.1%), arthromyalgia (17.9%), headache (8.4%), dysgeusia (6.2%), anosmia (5.5%)
Table 2. Final multivariable models.
Chronic pathologies model Disease severity Case fatality
Estimator Odds Ratio p Estimator Odds Ratio p
Age 0.01 1.01 (0.10–1.02) 0.224 0.08 1.08 (1.05–1.12) <0.001
Sex (female) -0.63 0.53 (0.35–0.80) 0.002 - - -
Diabetes Mellitus 0.28 1.32 (0.79–2.21) 0.293 0.54 1.71 (0.90–3.26) 0.100
Dyslipidemia 0.16 1.18 (0.74–1.87) 0.492 - - -
Obesity 0.74 0.09 (0.19–3.66) 0.010 - - -
Chronic kidney disease 0.43 1.154 (0.82–2.88) 0.177 0.41 1.51 (0.75–3.04) 0.250
Hypertension - - - 0.47 1.59 (0.74–3.43) 0.233
Heart failure - - - 0.15 1.16 (0.44–3.06) 0.768
Atrial fibrillation - - - 0.62 1.86 (0.86–4.02) 0.113
Dementia - - - 0.79 2.20 (0.99–4.85) 0.052
OSAS - - - 0.75 2.11 (0.77–5.73) 0.145
Auto-inmune disease - - - 0.82 2.28 (0.73–7.08) 0.156
Chronic medications model Disease severity Case fatality
Estimator Odds Ratio p Estimator Odds Ratio p
Age 0.01 1.01 (0.99–1.02) 0.080 0.09 1.10 (1.07–1.13) <0.001
Sex (female) -0.64 0.53 (0.35–0.80) 0.003 -0.64 0.53 (0.28–1.01) 0.052
Obesity 0.77 2.17 (1.24–3.79) 0.007 - - -
Corticosteroids 1.23 3.41 (1.08–10.71) 0.036 - - -
Metformin 0.47 1.61 (0.87–2.96) 0.130 - - -
Inhaled beta-2 0.47 1.60 (0.83–3.06) 0.158 - - -
Anticoagulants - - - 0.52 1.69 (0.73–3.88) 0.221
Antipsychotics - - - 1.74 5.69 (2.52–12.85) <0.001
OSAS: Obstructive sleep apnea syndrome.
https://doi.org/10.1371/journal.pone.0239571.t002
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and confusion (4.5%). Dyspnea was an important predictor of severe disease (OR 2.71, 95% CI
1.82–4.07), and confusion was an important predictor of death (OR 5.27 95% CI 2.03–13.93).
Fewer patients died whose reports reported diarrhea (OR 0.32 95% CI 0.15–0.63), arthromyal-
gia (OR 0.15 95% CI 0.04–0.43), headache (OR 0.26 95% CI 0.04–0.88) and alterations of smell
and taste (none of the 26 patients with smell and taste changes died; p<0.01). The presence of
asthenia was associated, on the other hand, with a lower risk of serious disease (OR 0.58 95%
CI 0.36–0.95). Notably, cough was strongly associated with a good prognosis (OR 0.16 95% CI
0.09–0.26), as patients with cough died much less frequently (9.4%) than those in whom this
symptom was not included in the emergency room reports (40.0%). To rule out that this result
was due to the action of age (elderly patients who are at risk of death, typically cough less), age
and cough were jointly entered into a multivariate predictive model of death. Both factors
turned out to be independent predictors (OR for cough in this model was 0.30; IC95% 0.17–
0.55). In addition, the protective role of cough remained in the less than 80 years old sample.
Strong baseline predictors for both severe disease and death were low baseline oxygen satu-
ration in the emergency department (means difference: 5.9% for severe disease and 8.1% for
death), high CRP in the emergency room analysis (means difference: 57 mg/L for severe dis-
ease, 63.1 mg/L for death) and the number of quadrants affected on chest radiography (means
difference: 0.7 quadrants for severe disease 0.6 quadrants for death). The above associations
were statistically significant with p value<0.001.
The mean time from symptom onset to emergency care was significantly longer in patients
who overcame the disease (8.0 days; SD 4.5) than in those who ended up dying (6.2 days; SD
4.7; p = 0.002). This effect was less marked in the subgroup of patients younger than 80 years
(time to emergency room care of the deceased: 6.5 days; SD 4.2; p = 0.053).
Laboratory analytical parameters
Patients admitted for COVID-19 presented leukocytosis with neutrophilia, eosinophilopenia and
lymphopenia. In addition, they presented elevated LDH and acute phase reactants (CRP and fer-
ritin), alterations in coagulation parameters (INR, fibrinogen, D-dimer), renal failure and alter-
ations in transaminases. The differences in these parameters between patients with and without
severe disease as well as between deceased patients and survivors can be seen in Table 3.
Multivariate models with different analytical parameters (logarithmic transformed and
scaled variables were used) showed that in the total sample, CRP was the best predictor of
severe disease (OR 2.33 95% CI 1.71–3.19) and eosinophilia (% of eosinophils) was an inde-
pendent protective factor (OR 0.67 95% CI 0.50–0.89). The predictive capacity of both parame-
ters remained independent when age and basal oxygen saturation was added to the model,
along with analytical parameters.
The risk of death was independently related to increased sodium levels (OR 2.24; IC95%
1.46–3.43), glucose levels (OR 1.62; IC95% 1.15–2.28), urea levels (OR 2.51; IC95% 1.61–3.90)
and decreased hemoglobin levels (OR 0.70; IC95% 0.52–0.95). When age and oxygen satura-
tion were added as co-variables, along with laboratory tests, only increased sodium levels
remained independently associated with death, along with age.
When these models were repeated in patients younger than 80 years, no analytical parame-
ter of those studied was an independent risk marker of death, although CRP remained inde-
pendent predictor of serious disease (OR 2.92; IC95% 1.80–4.74).
Discussion
Among the baseline factors associated with poor prognosis, obesity stands out as the specific
parameter of cardiovascular risk that is robustly associated with poor prognosis, being a better
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marker of poor prognosis than arterial hypertension or diabetes mellitus. In our environment,
Giacomelli et al. [10] also found that obesity was a risk factor (case fatality) in a cohort
(n = 233) of patients from Italy. This finding is important given its prevalence in Europe both
in the general population and in patients hospitalized with COVID-19 (20–25% and approxi-
mately 20%, respectively) [21]. In addition to the adverse mechanical effect on lung function
(decrease in forced expiratory volume and forced vital capacity), it has been proposed that the
metabolic alterations produced by COVID-19 could decrease cardiorespiratory reserves in the
face of a stressor, enhance dysregulation of the immune system, and favor a prothrombotic
and proinflammatory state, all of which are physiopathological phenomena relevant in SARS-
CoV-2 infection [22].
Regarding previous pharmacological treatments, we believe that the increased risk associ-
ated with antipsychotics may be due to age and dementia (which in turn is related to limitation
of therapeutic effort), rather than an intrinsic effect of these drugs. In our study, ACE inhibi-
tors were not associated with a worse prognosis, which has also been found by other authors
Table 3.
Total Mild disease Severe disease Survived Deceased
N Mean (SD) n Mean (SD) n Mean (SD) p n Mean (SD) n Mean (SD) p
Hemoglobin (g/L) 341 13,3 (1,9) 157 13,4 (1,8) 184 13,3 (2) 1,000 270 13,5 (1,8) 71,0 12,8 (2,2) 0,013
Platelets (10e9/L) 341 223,1 (96,0) 157 226,2 (96,3) 184 220,4 (96,0) 0,630 270 223,8 (96,0) 71,0 220,6 (96,9) 0,724
Neutrophils (10e9/L) 341 6 (3,7) 157 5,2 (3,2) 184 6,7 (4,1) 0,006 270 5,5 (3,3) 71,0 7,8 (4,6) <0,001
Neutrophils (%) 341 75,8 (11,8) 157 72,4 (11,0) 184 78,6 (11,8) 0,006 270 74,6 (11,1) 71,0 80,3 (13,3) <0,001
Lymphocytes (10e9/L) 341 1,1 (0,7) 157 1,2 (0,8) 184 1 (0,5) 0,001 270 1,1 (0,7) 71,0 1 (0,7) 0,069
Lymphocytes (%) 341 16,6 (9,5) 157 19,1 (9,4) 184 14,4 (9,0) 0,001 270 17,6 (9,1) 71,0 12,8 (10,1) 0,069
Eosinophils (%) 341 0,3 (0,6) 157 0,5 (0,8) 184 0,2 (0,5) <0,001 270 0,4 (0,7) 71,0 0,2 (0,4) 0,038
Prothrombin (INR) 334 1,2 (0,6) 154 1,1 (0,5) 180 1,2 (0,7) 0,195 263 1,1 (0,5) 71,0 1,4 (0,8) <0,001
D-dimer (ng/ml) 250 1875,2 (2719,3) 127 1461,3 (2266,8) 123 2299,4 (3070,5) <0,001 200 1436,9 (2071,1) 50,0 3628,6 (4029,3) <0,001
Glucose (mg/dL) 337 132,3 (55,9) 154 119,6 (40,8) 183 143,1 (64,1) <0,001 266 125,1 (51,3) 71,0 159,4 (63,8) <0,001
Sodium (mEq/L) 342 139 (5,3) 156 139,1 (5,0) 186 138,9 (5,6) 1,000 270 137,8 (3,5) 72,0 143,6 (8,0) <0,001
Creatinine (mg/dL) 342 1,2 (0,7) 157 1,1 (0,7) 185 1,3 (0,8) 0,004 271 1,0 (0,5) 71,0 1,7 (1,1) <0,001
Urea (mg/dL) 337 48 (40,5) 155 43,7 (41,5) 182 51,7 (39,3) 0,047 265 37,4 (24,8) 72,0 87,2 (59,1) <0,001
Alkaline phosphatase (UI/L) 241 82,6 (66,6) 119 77,9 (52,0) 122 87,2 (78,2) 0,869 206 83,4 (70,9) 35,0 77,5 (32,5) 1,000
AST (UI/L) 231 68,5 (241,8) 122 73,3 (328,7) 109 63,2 (58,9) 0,041 187 52,2 (45,6) 44,0 137,5 (545,7) 0,246
ALT (UI/L) 316 55,1 (91,4) 149 61,4 (124,4) 167 49,5 (44,9) 1,000 252 53,1 (48,2) 64,0 63,0 (180,2) 0,023
GGT (UI/L) 243 101,7 (197,5) 120 77,5 (70,0) 123 125,4 (267,4) 0,492 208 106,2 (212,4) 35,0 75,1 (48,0) 1,000
Bilirubin (mg/dL) 298 0,6 (0,5) 141 0,6 (0,6) 157 0,6 (0,4) 0,584 242 0,6 (0,5) 56,0 0,5 (0,3) 0,840
LDH (U/L) 268 326,5 (165,3) 132 283,2 (157,5) 136 368,5 (162,3) <0,001 216 310,7 (134,5) 52,0 392,1 (247,8) 0,006
CRP (mg/dL) 309 11,6 (10,7) 144 7,7 (6,5) 165 15,0 (12,4) <0,001 241 10,4 (10,1) 68,0 16,1 (11,9) 0,001
Ferritin (μg/L) 201 850,3 (1317,4) 99 550,0 (531,9) 102 1141,7 (1728,6) 0,014 171 828,0 (1258,1) 30,0 977,5 (1634,3) 0,840
Procalcitonin (ng/mL) 165 0,4 (0,8) 64 0,3 (0,7) 101 0,5 (0,9) 0,020 135 0,3 (0,7) 30,0 0,7 (1,1) 0,002
Lactate (mmol/L) 65 1,8 (1,2) 27 1,7 (0,9) 38 1,8 (1,4) 1,000 45 1,6 (0,8) 20,0 2,1 (1,8) 0,215
PaO2 (mmHg) 219 75,1 (28,6) 90 79,3 (28,5) 129 72,2 (28,5) 0,134 169 75,8 (25,8) 50,0 73,1 (36,9) 0,316
PaCO2 (mmHg) 219 24 (3,2) 90 24,2 (3,6) 129 23,9 (2,8) 0,915 169 24,1 (3,0) 50,0 23,9 (3,6) 0,786
HCO3– (mmol/L) 219 24,4 (2,5) 90 24,5 (2,7) 129 24,4 (2,3) 1,000 169 24,5 (2,4) 50,0 24,1 (2,9) 0,368
Ph 219 7,5 (0,0) 90 7,4 (0,0) 129 7,4 (0,0) 0,606 169 7,5 (0,0) 50,0 7,4 (0,0) 0,133
ALT: Aspartate-aminotransferasa. AST: Alanin-aminotransferase. CPR: C reactive protein. GGT: Gamma-glutamiltransferase. INR: international normalized ratio.
LDH: lactate dehydrogenase. PaO2: Partial pressure of oxygen. PaCO2 Partial pressure of CO2.
https://doi.org/10.1371/journal.pone.0239571.t003
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[15–17]. We emphasize that in our sample, oral corticosteroids were predictors, rather than
protectors, of death, which does not support the initial theories regarding their probable pro-
tective role. The Recovery clinical trial has recently showed that treatment with low dose dexa-
methasone decreases mortality in COVID-19 patients [23]. We have analyzed the prognostic
role of corticosteroids, when used before the onset of COVID-19 disease, not as a treatment
for it; therefore, we suggest that corticosteroids do not have a preventive role. Possibly cortico-
steroids are useful at certain stages of the disease, when inflammation is present, as the
RECOVERY trial researchers suggest in the publication of the results.
Regarding disease symptoms, notably, dyspnea was a marker of severe disease but not an
independent predictor of death. This could be related to the proposed hypothesis of “silent”
hypoxia as a clinical manifestation in some affected patients [24]. On the other hand, in our
sample, the great predictive capacity of cough (as a protector) with respect to death stands out.
Our results refute those of other studies in which it was found that cough was an adverse pre-
dictor of case fatality or severe disease [25, 26]; all of these studies involved exclusively Asian
cohorts. Additionally, fewer patients died who presented other nonrespiratory symptoms
(diarrhea, arthromyalgia, headache, and alterations in smell and taste). However, regarding
this result, we must recognize the possible existence of an information bias because the absence
of dyspnea (poor prognostic factor) could have led clinicians to investigate other symptoms;
therefore, these symptoms would have been collected with more frequency in patients without
dyspnea, who have a better prognosis. Mental confusion, as a presenting symptom, was a pre-
dictor of case fatality in our sample, which we believe is due to its relationship with age.
The strong predictive capacity of the parameters related to respiratory involvement (oxygen
saturation and number of observed radiological quadrants) and the inflammatory state (CRP
in the emergency room) coincides with that reported in other studies [27] that highlight the
prognostic importance of these factors. In addition, our study showed a shorter time of evolu-
tion of symptoms to emergency care in the group of patients who died (almost two days), with
respect to the survivors. This suggests that a longer presentation may be a reflection of less
aggressive disease, which is an interesting observation.
Regarding laboratory parameters upon admission, it is not surprising that CRP was the
most powerful predictor of severe disease given the role of inflammation in the disease. How-
ever, it is interesting to note that inflammatory parameters were not independent predictors of
case fatality in our sample. This finding, which contrasts with previous studies, it is possibly
due to the different profile of the Spanish population with respect to the Asian one [6, 7]; the
Spanish population has a greater burden of comorbidity, which may play an important role in
mortality associated to COVID-19.
The protective role of eosinophilia, independent of other laboratory parameters, has not
been evaluated or reported in previous studies. As eosinophilia was measured as a percentage
of eosinophils with respect to the total, it could also reflect a decrease in another cell series (for
example, neutrophils). If the protective role of eosinophilia is confirmed in other studies, this
finding may have practical utility, if considered in prognostic scales, in addition to contribut-
ing to future knowledge on immune system reactions against SARS-CoV-2.
Our study was carried out on a hospitalized sample, so its results may not be applicable to
patients with milder disease, who did not require hospitalization. Notably, our results involve
a cohort from secondary hospitals (intermediate complexity) and a specific geographical area,
which limits the generalization of the results to other cohorts, especially those of patients hos-
pitalized in tertiary hospital centers (maximum complexity). Although we have an intensive
care unit that doubled its capacity at the peak of the epidemic, it is likely that some of the most
severe patients were transferred to tertiary hospitals and therefore remained underrepresented
in our cohort.
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Another limitation that should be mentioned is possible information bias because data
extracted from clinical histories were used; these data were collected to guarantee the clinical
care of the patients and not for the purpose of this research. This can affect the recording of
extrapulmonary symptom presentation, as previously discussed. However, given that the
majority of variables recorded are routinely used in clinical practice and are recorded reliably,
for the best care of patients, we assume that if there was an information bias, this was limited
or of little impact on the analyses.
In summary, advanced age, male sex and obesity were the main markers of poor prognosis
in patients with COVID-19. The most frequent presenting symptom was fever; dyspnea was
associated with severe disease, and the presence of cough was associated with greater survival.
Low oxygen saturation in the emergency room, elevated CRP in the emergency room and ini-
tial radiological involvement were all related to worse prognosis.
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clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney International. 2020 Jul 1; 98
(1):27–34. https://doi.org/10.1016/j.kint.2020.04.031 PMID: 32437770
12. Rodrı́guez-Cola M, Jiménez-Velasco I, Gutiérrez-Henares F, López-Dolado E, Gambarrutta-Malfatti C,
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13. Sánchez-Álvarez JE, Pérez Fontán M, Jiménez Martı́n C, Blasco Pelı́cano M, Cabezas Reina CJ, Sevil-
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